Workshop IV-2 - Pharmacology and Novel Therapies: Inhibition of Cholesterol Synthesis and/or Cholesterol Absorption
Abstract: 582 ATTAINMENT OF SINGLE/DUAL TREATMENT LEVELS FOR LDL-C AND NON-HDL-C, APOB, OR HS-CRP IN PATIENTS WITH METABOLIC SYNDROME (MS): EZETIMIBE(E)/SIMVASTATIN(S) VS ATORVASTATIN(A)